Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
6 Months : From May 2019 to Nov 2019
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs). The ability to engineer highly specific gene editing nucleases with little or no detectable activity at unintended genomic sequences is a key safety factor for therapeutic applications. The strategies entail engineering the two key functional regions within the ZFN structure, namely adjusting the binding affinity of the zinc finger array which recognizes DNA, and slowing the catalytic rate of the Fok1 cleavage domain. The two approaches, which are complementary, may be combined to enable near 100% on-target modification with no detectable off-targets. The manuscript, titled “Enhancing gene editing specificity by attenuating DNA cleavage kinetics,” was published online on July 29 and will appear in the August issue of Nature Biotechnology.
“When attempting to improve the specificity of genome editing tools, on-target editing efficiency is often sacrificed,” said Edward Rebar, Ph.D., Chief Technology Officer, Sangamo. “With these new strategies, the high efficiency we have observed previously with ZFN-mediated genome editing was completely preserved, while off-target activity was reduced by approximately 1000-fold, to below the level of detectability. These results are important as we believe the capabilities they demonstrate will help ensure the safety of our genome editing tools when used in the clinic.”
In order to adjust the binding affinity of the zinc finger recognition domain, the authors substituted a discrete, positively charged residue in the zinc finger framework to eliminate a nonspecific contact with the negatively charged phosphate backbone of the DNA. By varying the number of fingers bearing this substitution, the authors showed in cellular studies that they could effectively tune ZFN affinity into an optimally specific range, with no loss of on-target efficiency.
In a related series of cellular studies, the authors screened single-amino acid substitutions in the Fok1 nuclease domain in order to identify those able to improve specificity by slowing down catalysis. The goal of the study was to observe whether mutations would provide more time for the ZFNs to selectively dissociate from off-target sites prior to a cleavage event, which would improve global specificity. These studies yielded single-residue substitutions that could increase specificity by more than 1000-fold.
In a final study detailed in the manuscript, Sangamo scientists applied these two strategies in a therapeutically relevant setting by designing ZFNs that targeted the endogenous TCR-alpha gene in T-cells. Treatment of these T-cells with optimized ZFNs resulted in a greater than 98% on-target knockout efficiency of the TCR-alpha gene with undetectable off-target activity at a median assay background level of 0.01%. Sangamo believes these engineered improvements to the specificity of its ZFN genome editing platform have the potential to enable the routine generation of designed nucleases capable of high efficiency editing with minimal or no detectable off-target activity.
These results add to Sangamo’s body of research demonstrating the high degree of precision, efficiency, and specificity of ZFNs for genome editing. In March 2019, Nature Communications published data demonstrating new ZFN architectures enabling high-precision genome editing. These new architectures yielded a 64-fold increase in the diversity of ZFNs available for targeting any DNA segment.
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com
This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to the ability to engineer the ZFN structure to enable on-target modification, the effects of these strategies on Sangamo’s genome editing tools, the safety attributes associated with these strategies and their ability to help ensure the safety of Sangamo’s gene editing tools in the clinic, whether or not these effects may be replicated in the clinic, the potential for these engineered improvements to improve specificity on designed nucleases, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to: early preclinical data, including the risk that the early preclinical data may not warrant regulatory approvals to conduct any human clinical trials, and may not be representative of the results of any such human clinical trials; whether Sangamo’s gene editing tools and strategies will produce any beneficial therapeutic effect in humans; Sangamo's ability to develop commercially viable products; and the potential for technological developments by Sangamo's competitors that will obviate Sangamo's ZFN technology. These risks and uncertainties are described more fully in Sangamo's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 as filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005175/en/
Investor Relations – United States
Media Inquiries – United States
Investor Relations and Media Inquiries – European Union
33 4 97 21 27 27